Aerovate Therapeutics Inc
Research Aerovate Therapeutics Inc (JBIO) on Bullrun: market cap USD 889.79M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerJBIO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 889.79M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 55.77M
- Free cash flow-USD 43.66M
Valuation Snapshot
latest market cap is USD 889.79M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 127.41M | -USD 94.89M | n/a | -3.19 | USD 88.44M | USD 724.00K | USD 332.52M |
| FY2024 | n/a | -USD 69.63M | n/a | n/a | -2.44 | USD 69.39M | USD 107.60M | -USD 46.80M |
| FY2023 | n/a | -USD 75.52M | -USD 56.92M | n/a | -2.87 | USD 23.49M | n/a | USD 109.46M |
| FY2022 | n/a | -USD 51.51M | -USD 39.32M | n/a | -2.1 | USD 22.40M | n/a | USD 126.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 889.79M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 760.95M | n/a | 15.6% | 2.4 |
Dividend history
| Year | Dividends/share |
|---|---|
| FY2025 | 2.4 USD |
About Aerovate Therapeutics Inc
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aerovate Therapeutics Inc's market cap?
Aerovate Therapeutics Inc's market capitalization is USD 889.79M.
What does Aerovate Therapeutics Inc do?
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.